{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:45:15Z","timestamp":1793094315496,"version":"4.5.0"},"reference-count":43,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-016826"],"award-info":[{"award-number":["INV-016826"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2024,4,3]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine the effects of fish oil supplements on the clinical course of cardiovascular disease, from a healthy state to atrial fibrillation, major adverse cardiovascular events, and subsequently death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Prospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>UK Biobank study, 1 January 2006 to 31 December 2010, with follow-up to 31 March 2021 (median follow-up 11.9 years).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>415\u2009737 participants, aged 40-69 years, enrolled in the UK Biobank study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Incident cases of atrial fibrillation, major adverse cardiovascular events, and death, identified by linkage to hospital inpatient records and death registries. Role of fish oil supplements in different progressive stages of cardiovascular diseases, from healthy status (primary stage), to atrial fibrillation (secondary stage), major adverse cardiovascular events (tertiary stage), and death (end stage).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 415 737 participants free of cardiovascular diseases, 18 367 patients with incident atrial fibrillation, 22 636 with major adverse cardiovascular events, and 22 140 deaths during follow-up were identified. Regular use of fish oil supplements had different roles in the transitions from healthy status to atrial fibrillation, to major adverse cardiovascular events, and then to death. For people without cardiovascular disease, hazard ratios were 1.13 (95% confidence interval 1.10 to 1.17) for the transition from healthy status to atrial fibrillation and 1.05 (1.00 to 1.11) from healthy status to stroke. For participants with a diagnosis of a known cardiovascular disease, regular use of fish oil supplements was beneficial for transitions from atrial fibrillation to major adverse cardiovascular events (hazard ratio 0.92, 0.87 to 0.98), atrial fibrillation to myocardial infarction (0.85, 0.76 to 0.96), and heart failure to death (0.91, 0.84 to 0.99).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Regular use of fish oil supplements might be a risk factor for atrial fibrillation and stroke among the general population but could be beneficial for progression of cardiovascular disease from atrial fibrillation to major adverse cardiovascular events, and from atrial fibrillation to death. Further studies are needed to determine the precise mechanisms for the development and prognosis of cardiovascular disease events with regular use of fish oil supplements.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjmed-2022-000451","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:00:13Z","timestamp":1716321613000},"page":"e000451","source":"Crossref","is-referenced-by-count":36,"title":["Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study"],"prefix":"10.1136","volume":"3","author":[{"given":"Ge","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengmin (Min)","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-6565","authenticated-orcid":false,"given":"Zilong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Vaughn","sequence":"additional","affiliation":[{"name":"School of Social Work, College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E","family":"Aaron","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangshi","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Research and Biometrics Centre, Fuwai Hospital, National Centre for Cardiovascular Diseases, Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory YH","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-9408","authenticated-orcid":false,"given":"Hualiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2025080501023606000_3.1.e000451.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"2025080501023606000_3.1.e000451.2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/STROKEAHA.120.032692","article-title":"Association between stroke and subsequent risk of suicide: a systematic review and meta-analysis","volume":"52","author":"Vyas","year":"2021","journal-title":"Stroke"},{"key":"2025080501023606000_3.1.e000451.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60445-X"},{"key":"2025080501023606000_3.1.e000451.4","unstructured":"National Institute for Health and Care Excellence . Guidelines. cardiovascular disease: risk assessment and reduction, including lipid modification. London National Institute for Health and Care Excellence (NICE); 2016. Available: https:\/\/www.nice.org.uk\/guidance\/ng238?UID=3279581122023122671124"},{"key":"2025080501023606000_3.1.e000451.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001031"},{"key":"2025080501023606000_3.1.e000451.6","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072421","article-title":"Beneficial outcomes of omega-6 and omega-3 polyunsaturated fatty acids on human health: an update for 2021","volume":"13","author":"Djuricic","year":"2021","journal-title":"Nutrients"},{"key":"2025080501023606000_3.1.e000451.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812792"},{"key":"2025080501023606000_3.1.e000451.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c6273","article-title":"Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial","volume":"341","author":"Galan","year":"2010","journal-title":"BMJ"},{"key":"2025080501023606000_3.1.e000451.9","doi-asserted-by":"publisher","DOI":"10.1097\/HJR.0b013e328339cc70"},{"key":"2025080501023606000_3.1.e000451.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811403"},{"key":"2025080501023606000_3.1.e000451.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"2025080501023606000_3.1.e000451.12","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx246"},{"key":"2025080501023606000_3.1.e000451.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx254"},{"key":"2025080501023606000_3.1.e000451.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m456","article-title":"Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study","volume":"368","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"2025080501023606000_3.1.e000451.15","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2245","article-title":"Schizophrenia, bipolar disorder, or intracranial aneurysm? A case report","volume":"11","author":"Shi","year":"2021","journal-title":"Brain Behav"},{"key":"2025080501023606000_3.1.e000451.16","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacep.2021.05.013","article-title":"Risk thresholds for total and beverage-specific alcohol consumption and incident atrial fibrillation","volume":"7","author":"Tu","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"2025080501023606000_3.1.e000451.17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712"},{"key":"2025080501023606000_3.1.e000451.18","doi-asserted-by":"crossref","unstructured":"LCd W , Fiocco M . mstate: anrpackage for the analysis of competing risks and multi-state models. J Stat Softw 2011;38. doi:10.18637\/jss.v038.i07","DOI":"10.18637\/jss.v038.i07"},{"key":"2025080501023606000_3.1.e000451.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02573-0","article-title":"Ambient air pollution associated with incidence and dynamic progression of type 2 diabetes: a trajectory analysis of a population-based cohort","volume":"20","author":"Wu","year":"2022","journal-title":"BMC Med"},{"key":"2025080501023606000_3.1.e000451.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22258"},{"key":"2025080501023606000_3.1.e000451.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.055654"},{"key":"2025080501023606000_3.1.e000451.22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.314541"},{"key":"2025080501023606000_3.1.e000451.23","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25010128","article-title":"Concentration-dependent effects of N-3 long-chain fatty acids on NA,K-ATPase activity in human endothelial cells","volume":"25","author":"Cazzola","year":"2019","journal-title":"Molecules"},{"key":"2025080501023606000_3.1.e000451.24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10840-009-9466-8","article-title":"Fatty acid percentage in erythrocyte membranes of atrial flutter\/fibrillation patients and controls","volume":"27","author":"Viviani Anselmi","year":"2010","journal-title":"J Interv Card Electrophysiol"},{"key":"2025080501023606000_3.1.e000451.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025080501023606000_3.1.e000451.26","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(21)02811-4","article-title":"Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term MACE in those with and without angiographic CAD","volume":"77","author":"Le","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025080501023606000_3.1.e000451.27","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000014682.14181.F2"},{"key":"2025080501023606000_3.1.e000451.28","doi-asserted-by":"crossref","first-page":"105060","DOI":"10.1016\/j.phrs.2020.105060","article-title":"Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials","volume":"160","author":"Casula","year":"2020","journal-title":"Pharmacol Res"},{"key":"2025080501023606000_3.1.e000451.29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025080501023606000_3.1.e000451.30","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-019-0763-0","article-title":"Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials","volume":"21","author":"Jia","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"2025080501023606000_3.1.e000451.31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/VHRM.S210149","article-title":"Spotlight on icosapent ethyl for cardiovascular risk reduction: evidence to date","volume":"16","author":"Jia","year":"2020","journal-title":"Vasc Health Risk Manag"},{"key":"2025080501023606000_3.1.e000451.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61239-8"},{"key":"2025080501023606000_3.1.e000451.33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017401","article-title":"Plasma omega-3 fatty acids and the risk of cardiovascular events in patients after an acute coronary syndrome in MERLIN-TIMI 36","volume":"10","author":"Zelniker","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025080501023606000_3.1.e000451.34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s11010-020-03965-7","article-title":"Omega-3 polyunsaturated fatty acids: anti-inflammatory and anti-hypertriglyceridemia mechanisms in cardiovascular disease","volume":"476","author":"Shibabaw","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"2025080501023606000_3.1.e000451.35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00125-020-05300-7","article-title":"Effects of long-term vitamin D and N-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial","volume":"64","author":"Limonte","year":"2021","journal-title":"Diabetologia"},{"key":"2025080501023606000_3.1.e000451.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2014.08.010"},{"key":"2025080501023606000_3.1.e000451.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.07.035"},{"key":"2025080501023606000_3.1.e000451.38","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu024"},{"key":"2025080501023606000_3.1.e000451.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.063"},{"key":"2025080501023606000_3.1.e000451.40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147558","article-title":"Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines","volume":"131","author":"Bornfeldt","year":"2021","journal-title":"J Clin Invest"},{"key":"2025080501023606000_3.1.e000451.41","doi-asserted-by":"publisher","DOI":"10.1097\/00043798-199710000-00011"},{"key":"2025080501023606000_3.1.e000451.42","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-316780"},{"key":"2025080501023606000_3.1.e000451.43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014343"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2022-000451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:02:45Z","timestamp":1754380965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2022-000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjmed-2022-000451"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2022-000451","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}